glp-1 receptor agonist agent Agonists and Other Drugs A Closer Look at the

Acknowledgments GNP is supported by funding from the Canadian Institutes of Health Research (CIHR)

For more information, visit our partners page.

Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes

Abbreviations ARB: Angiotensin receptor blocker CKD: Chronic kidney disease CRP: C-reactive protein DKA: Diabetic ketoacidosis DKD: Diabetic kidney disease ERA: Endothelin receptor antagonist ESKD: End-stage kidney disease GIP: Glucose-dependent insulinotropic polypeptide GLP1: Glucagon-like peptide 1 GLP1-RA: Glucagon-like peptide 1 receptor agonist HF: Heart failure hsCRP: High-sensitivity C-reactive protein MACE: Major adverse cardiovascular events MRA: Mineralocorticoid receptor antagonist NO: Nitric oxide RAS: Reninangiotensin system sGC: Soluble guanylate cyclase SGLT2i: Sodiumglucose cotransporter-2 inhibitor(s) UACR: Urine albumin to creatinine ratio References Rossing P, Caramori ML, Chan JCH et al (2022) KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease